Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
-$8,000 |
 |
AmgenAMGN |
$67,000 |
 |
Editas MedicineEDIT |
-$8,000 |
 |
Alnylam PharmaceuticalsALNY |
-$16,000 |
 |
United TherapeuticsUTHR |
-$210,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Daniel S. Goldman Democrat | Mar 31, 2023 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat | Feb 27, 2023 | Buy | $1K - $15K |
Who is the latest politician to buy or sell Grifols shares?
Daniel S. Goldman sold Grifols shares most recently on March 31, 2023.
Which politician has bought the most GRFS stock in the last two years?
Daniel S. Goldman has bought the most GRFS stock in the last 2 years, with an estimated value of $8,000.
Which politician has sold the most GRFS stock over the last two years?
Daniel S. Goldman has sold the most GRFS stock in the last 2 years, with an estimated value of $8,000.
What is the total value of politicians trading GRFS stock in the last 2 years?
There have been no US politicians buying or selling Grifols in the last 2 years.
How do insider transactions over the last 2 years reflect on Grifols' market confidence?
Over the last 2 years, insider transactions for Grifols have been balanced between buying and selling, showing a neutral stance among insiders towards the company's market performance. This trend of more purchases than sales could be a positive signal to potential investors about the politicians view on the company's future and growth potential.
Why should individual investors pay attention to the stock transactions of US politicians?
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
